Perspective
Perianal Fistulizing Crohn’s Disease: A Call to Action

https://doi.org/10.1016/j.cgh.2007.10.010Get rights and content

The advent of biological therapies has focused attention on the importance of healing luminal Crohn’s disease, thereby modifying the disease course. Perianal fistulas are common in Crohn’s disease and often have a poor prognosis, with permanent sphincter and perineal tissue destruction. The importance of healing these fistulas has been less well appreciated. Management still often is left in surgical hands alone, rather than the optimal combination of surgery, infection control, and immunosuppression. Drug therapy often is haphazard, and the means of assessing healing over a long time period has been characterized poorly. Recent studies have suggested that many of these patients can achieve fistula healing, at least in the medium term. We therefore call for more active intervention, with the goal of healing, in these sick patients. Perianal fistulas lead to substantial physical and emotional distress because of pain, discharge, incontinence, perineal and genital disfigurement, and slow resolution even with treatment. The advent of accurate anal imaging, improved knowledge of surgical outcomes, and potent biological therapies make it timely to reflect on current best-management strategies.

References (34)

  • S.J. Bell et al.

    Clinical course of fistulating Crohn’s disease

    Aliment Pharmacol Ther

    (2003)
  • A. Armuzzi et al.

    Genotype-phenotype analysis of the Crohn’s disease susceptibility haplotype on chromosome 5q31

    Gut

    (2003)
  • J. Satsangi et al.

    The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications

    Gut

    (2006)
  • P.J. Lunniss et al.

    Factors affecting continence after surgery for anal fistula

    Br J Surg

    (1994)
  • T. Yamamoto et al.

    Effect of fecal diversion alone on perianal Crohn’s disease

    World J Surg

    (2000)
  • J.G. Guillem et al.

    Factors predictive of persistent or recurrent Crohn’s disease in excluded rectal segments

    Dis Colon Rectum

    (1992)
  • D.C. Pearson et al.

    Azathioprine and 6-mercaptopurine in Crohn diseaseA meta-analysis

    Ann Intern Med

    (1995)
  • Cited by (0)

    1

    Michael Kamm has received research support and has acted as a consultant to Schering-Plough, Herts, UK and Abbott, Berkshire, UK.

    View full text